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Background: Morinda lucinda (Benth) Rubiaceae has been reported in folk medicine to be useful for the treatment of 
diabetes mellitus (DM) and hyperlipidemia. Previous studies have identified the hypoglycemic effect of this herb, but 
data on its lipid lowering effect is lacking.  
Objective: To evaluate the effect of Morinda lucinda on hyperlipidemia. 
Methods: Morinda lucinda roots were extracted via cold maceration using distilled water. It was administered to rats 
(n=6 per group) on a high cholesterol diet for 14 days (40 mg/rat/day). Five groups of rats were orally given the 
extract (100, 200 and 400 mg/kg), atorvastatin (5mg/kg), or distilled water (2ml/kg) for 14 days. Positive and 
negative control groups received cholesterol & distilled water and only distilled water respectively. After the 14th day, 
blood samples were withdrawn and separated plasma was tested for HDL, LDL, triglycerides and total cholesterol.  
Results: Treatment with Morinda lucinda extract at all doses significantly reduced the levels of LDL (p <0.0001), while 
increasing the HDL levels (p<0.05) in the hyperlipidemic rats from 12.5 mg/dL to 24.2, 23.93, 26.67 mg/dL for the 3 
doses respectively. Similarly, administered extract at all doses significantly reduced the total cholesterol (p<0.0001) 
and triglycerides (p = 0.001, p = 0.0005, and p<0.0001 for 100, 200 and 400 mg/kg respectively) in comparison with 
the positive control. The effect of the extract on total cholesterol and LDL were most prominent and was as effective 
as atorvastatin. 
Conclusions: The effect of the extract on total cholesterol and LDL were most prominent and was as effective as 
atorvastatin. Our results suggest Morinda lucinda as a useful remedy for lowering lipid level in patients 
with hyperlipidemia. 
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1. Introduction 
Morinda lucida (Benth), Rubiaceae is a medium-sized 
tree, 15m in height and has a characteristic yellow 
wood, from which it derives its common name 
“Brimstone tree. The name Morinda is derived from the 
Latin word ‘morus’ meaning ‘mullberry’ from the 
appearance of the fruits.  Local names in Nigeria 
includes: Oruwo (South-West); Eze ogu (South East); 
Mangwara or Waawan kurmii (North).  
In a study carried out on the ethanol and 
dichloromethane extract of the plant, the roots and 
leaves of Morinda lucida were found to contain volatile 
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oils, methyl anthraquinones, saponins, alkaloids, sterols, 
tannins and cardenolide (Adomi, 2008).   
Different parts of the plant are associated with diverse 
therapeutic benefits. The leaves are used in the 
preparation of fever teas, which are used as 
antimalarial, febrifuge and as an analgesic agent. All 
parts of the plant are used as a laxative (Iwu, 2014). In 
folk medicine in Nigeria, the plant is macerated in palm 
wine or water and its decoction used in the 
management of diabetes mellitus viz-a-vis 
hyperlipidemia (Adeneye and Agbaje, 2008). 
Hyperlipidemia is a raised serum or plasma levels of 
one or more of the following; total cholesterol (TChol), 
Low density Lipoproteins (LDL-C), Triglycerides (TGs), 
or a combination of any or all of the above. Usually the 
condition may be associated with a decrease in High 
density Lipoprotein (HDL). It can be classified either as 
familial also called “primary”- caused by specific genetic 
abnormalities, or as secondary also called “acquired”, 
when resulting from another underlying disorder that 
leads to alterations in plasma lipid and/or lipoprotein 
metabolism, such as diabetes mellitus DM, drugs (beta 
blockers, estrogens, diuretics), hypothyroidism,  or 
renal failure (Chait and Brunzell, 1990). 
Another classification is done based on the exact type(s) 
of lipids that is/are elevated, hence one could have 
hypercholesterolemia, hypertriglyceridemia or 
hyperlipoproteinemia (in which total cholesterol, 
triglycerides or lipoproteins are increased) respectively 
(Chait and Brunzell, 1990).  
It is well established that individuals may have 
anomalies in their lipid levels. This also applies to 
individuals with DM, the common cause of secondary 
hyperlipidemia. In DM there is either total lack or 
insufficient insulin or there is tissue receptor resistance 
to insulin (Type 1 and Type 2). Lipoprotein lipase 
activated by insulin is an enzyme responsible for 
splitting the LDLs and chylomicrons into HDLs. In the 
absence of insulin this enzyme is not activated and LDLs 
and chylomicrons accumulate in the blood stream thus 
increasing the risk of hyperlipidemia in poorly managed 
DM.  
This research was done basically to investigate the 
claim that the hyperlipidemia usually associated with 
hyperglycaemia can be corrected alongside the 
hyperglycaemia using extracts of Morinda lucida. The 
objective of this study therefore was to examine the 
antihyperlipidemic effect of Morinda lucida.  
2. Materials and Methods 
2.1 Plant collection and preparation 
The fresh roots of Morinda lucida were collected in 
Benin City, Edo state, Nigeria in July, 2014. 
Identification of the plant was done by Mr Sunny Nweke 
a herbarium curator, in the Department of 
Pharmacognosy, Faculty of Pharmacy, University of 
Benin, Benin City, Edo state, Nigeria and a voucher 
specimen was deposited in the departmental 
herbarium. A voucher specimen (FHI 107459) also 
exists at the Forest Research Institute of Nigeria, 
Ibadan, Nigeria. 
Immediately after collection, the roots were washed 
with water to remove soil particles, after which they 
were chopped into smaller pieces and then air dried. It 
was then pulverized into a smooth fine powder using an 
Impact mill. The powdered sample was weighed and 
kept for further analysis. 
2.2 Plant Extraction 
The powdered plant material (500 g) was macerated in 
2500 ml of distilled water with continuous stirring for 
72 h. The mixture was initially filtered using a clean 
white plain cloth to obtain a debris-free solution which 
was then further filtered using a funnel and cotton 
plugs. The resulting solution was then placed in the 
oven (< 40 ̊C) for drying and a solid residue was 
obtained and weighed (42.19 g) and the percentage 
yield was calculated (8.44%). Appropriate 
concentrations of the extract were made in distilled 
water for the experiment. 
2.3 Drugs and chemicals 
Cholesterol powder (Kelong Chemicals (Xindu Mula, 
India), Atorvastatin tablets (Evans Pharmaceuticals, 
Lagos, Nigeria), Chloroform (Sigma Aldrich UK), Total 
cholesterol kit, HDL kit and Triglycerides kit (Randox 
Laboratories, UK). 
2.4 Study Animals 
Wister albino rats (170-310 g) of either sex were used. 
Animals were kept at the laboratory animal house of the 
Department of Pharmacology and Toxicology, Faculty of 
Pharmacy, University of Benin. The animals were 
maintained and kept in cages in a room with a 12-hour 
light and dark cycle for two (2) weeks to acclimatize. 
The animals were allowed free access to water and food 
(pelleted feed; Top Feed, Nigeria). 
2.5 Phytochemical screening 
Qualitative chemical tests were performed to assess the 
presence of the various phytochemical constituents of 
the Morinda lucida aqueous root extract (Trease and 
Evans, 1989). 
2.6 Experimental protocol 
Formula of high cholesterol diet and dosing of 
animals 
The high cholesterol diet was prepared by suspending 
200 mg of Cholesterol powder in 1 ml Olive oil to give a 
suspension of 40 mg in 0.2 ml. This was administered 
orally via an orogastric tube daily for 14 days to 
selected groups of animals as described below.  
The albino rats were divided into 8 groups of 6 rats 
each and treated as follows:  
Group 1-Control group (2 ml/kg) of distilled water 
only; 
Group 2-Hyperlipidemic group; Cholesterol (40 
mg/0.2 ml/rat) only;  
Group 3- 100 mg/kg of the extract only;  
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Group 4- 200 mg/kg of the extract only;  
Group 5- Cholesterol (40 mg/rat) and 100 mg/kg 
extract;  
Group 6- Cholesterol (40 mg/0.2 ml/rat) and 200 
mg/kg extract;  
Group 7- Cholesterol (40 mg/0.2 ml/rat) and 400 
mg/kg extract; and  
Group 8- Cholesterol (40 mg/0.2 ml/rat) and 
Atorvastatin 5 mg/kg.  
All doses were administered by the oral route using an 
orogastric tube once daily for 14 days (Nnodim et al, 
2011) - this constituted sub-acute treatment.  
Determination of lipid profile parameters. 
Twenty-four hours after administration of the last dose, 
the animals were sacrificed under chloroform 
anesthesia and then blood samples were collected via 
the abdominal aorta. The samples collected were 
transferred into lithium heparinized tubes. The tubes 
were centrifuged at 4000 rpm for 3 min. Clear plasma 
sample was obtained and transferred carefully with the 
aid of a micropipette (500 microliters) into small test 
tubes for estimation. Plasma samples were stored in -
20°C refrigerator prior to analysis.  
The plasma concentration of the total cholesterol, high 
density lipoproteins and triglycerides were measured 
by standard procedures using commercial analytical kit 
from Randox Laboratory Limited, UK. The total 
cholesterol was determined after enzymatic hydrolysis 
and oxidation. The indicator quinoneimine is formed 
from hydrogen peroxide and 4-aminoantipyrine in the 
presence of phenol and peroxidase. Distilled water 
(blank), cholesterol standard, and sample (5 ml each) 
were pipetted into 3 different cuvettes. Reagent (500 
µL) was added to each the cuvettes containing the 
sample.  The contents in the cuvettes were mixed and 
incubated for 5min at 37°C. The cuvettes were then 
inserted into the UV spectrophotometer to read the 
absorbance of the blank, standard and the sample 
(Allain et al, 1982; Roeschlau et al, 1974). The 
concentration of cholesterol in each of these samples 
was calculated from the absorbance. Similar procedure 
and formula was used to determine the concentration of 
plasma triglycerides and High density lipoproteins 
using their appropriate reagents.  
The Low density lipoproteins was calculated using a 
formula:  
LDL = TC- (TG/5 + HDL)     
Where:  LDL- Low density lipoproteins 
   HDL- High density lipoproteins 
   TC- Total cholesterol  
   TG- Triglyceride. 
 
2.7 Statistical analysis. 
Data are presented as the mean ± standard error of the 
mean (S.E.M). Comparisons were made where 
appropriate by One way ANOVA (GraphPad Prism 
Software, UK, version  2.05a) with Tukey post hoc test. 
2.8 Ethical approval. 
Ethical approval was obtained from the ethical 
committee of the Faculty of Pharmacy, University of 
Benin, Benin City, Edo state, Nigeria. Approval letter 
dated October 10th, 2014, and animals were handled 
according to the standard protocols for the use of 
laboratory animals (National Institute of Health, USA, 
2002).  
3.  Results 
3.1 Phytochemical screening of the aqueous root 
extract of Morinda lucida. 
The result of the preliminary phytochemical screening 
is shown in Table 1, it revealed the presence of 
carbohydrates, saponins, alkaloids, glycosides and 
steroids. Phenols and tannins were absent. 
Table 1: Phytochemical screening of the aqueous root 
extract of Morinda lucida 
Secondary metabolites Result 
Carbohydrates + 
Saponins + 
Phenols - 
Tannins - 
Alkaloids + 
Steroids  + 
   + Present; -  Absent 
3.2 The effect of different doses of Morinda lucinda 
on the total cholesterol  
These results are shown in Figure 1. Administration of 
ML to normal rats had no significant effect on their total 
cholesterol (p>0.05) when compared to the control 
group. The significant increase (p<0.05) in the total 
cholesterol observed in the hyperlipidemic group in 
comparison with the control was however noted to be 
significantly reduced (p<0.05, p<0.0001 and p<0.05) for 
100, 200 and 400 mg/kg doses respectively in 
comparison with the hyperlipidemic group (cholesterol 
only group) after 14 days treatment with the aqueous 
root extract of ML. The effect of the extract was similar 
to that of atorvastatin at a dose of 5mg/kg in which the 
total cholesterol was also significantly reduced (p 
<0.05) when compared to the Cholesterol-only group.  
It was however noted that this effect was non-dose 
dependent as the 200 mg/kg dose gave the highest 
reduction. 
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3.3 The effect of different doses of Morinda lucida 
on the triglycerides  
A significant increase (p<0.05) in the triglycerides was 
observed in the hyperlipidemic group in comparison 
with the control animals. Interestingly, treatment with 
the aqueous root of Morinda lucida at all doses (100, 
200 and 400 mg/kg) produced a significant decrease (p 
= 0.005, p = 0.001 and p< 0.0001) respectively in the 
plasma triglyceride levels when compared to the 
hyperlipidemic group. In this case the decrease may be 
said to be dose dependent because of the graded 
difference between values of plasma triglycerides 
obtained for the 3 different doses used as was observed 
in the previous result on total cholesterol the extract 
also seems not to have any significant effect on the 
triglycerides of normal rats. This comparison was done 
with the control group administered with distilled 
water (Figure 2). 
 
  
Figure 1: The effect of Morinda lucinda on the total 
cholesterol of normal and high cholesterol fed rats. 
Figure 2: The effect of Morinda lucinda on the 
triglycerides of normal and high cholesterol fed rats 
  
Figure 3: The effect of Morinda lucinda on the HDL of 
normal and high cholesterol fed rats 
Figure 4: The effect of Morinda lucinda on the LDL of 
normal and high cholesterol fed rats 
Values are expressed as Mean ± S.E.M for the animals in each group. 
n= 6; #p<0.05 and ap<0.05 significantly higher and lower than the control group respectively and *p < 0.0001 significantly lower than the 
cholesterol only group.  
N: Control group (2ml/kg) of distilled water only. 
C: Hyperlipidemic group, cholesterol only. 
ML100: 100mg/kg of the extract only. 
ML200: 200mg/kg of the extract only. 
CML100: Cholesterol and 100 mg/kg extract.  
CML200: Cholesterol and 200 mg/kg extract.  
CML400: Cholesterol and 400 mg/kg extract.  
CA5: Cholesterol and 5 mg/kg atorvastatin.  
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3.4 The effect of different doses of Morinda lucida 
on the high density lipoprotein  
These results are shown in Figure 3. The aqueous root 
extract of Morinda lucida at 100, 200 and 400 mg/kg 
(p< 0.0001), (p< 0.05), (p< 0.01) significantly increased 
the plasma HDL levels respectively when compared to 
the Cholesterol-only group (the hyperlipidaemic group). 
This increase in HDLs was higher when compared to the 
standard drug (Atorvastatin 5mg/kg).  The increase can 
be said not to be dose dependent because of the 
comparable values of HDLs observed in 100 200 and 
400 mg/kg (mean values of 24.20, 23.93 and 26.67 
mg/dL respectively). 
3.5 The effect of different doses of Morinda lucinda 
on the low density lipoprotein  
The result is presented in Figure 4. A careful look at the 
result shows a reduction of the LDL in normal rats in 
comparison with the control group administered 
distilled water. This reduction was seen again in rats 
placed on a high cholesterol diet. Both 100 and 200 
mg/kg significantly (p<0.05) lowered the LDL of normal 
rats, while the 3 doses used (100, 200 and 400 mg/kg) 
produced significant reduction in the plasma LDL levels 
when compared to the hyperlipidemic group 
(Cholesterol-only group) with p values <0.0001 for all 
doses tested, the reduction here is said to be non-dose 
dependent because the decrease in the values obtained 
were not graded. 
The effect of different doses of Morinda lucinda on 
the Atherogenic index (AIP) of normal rats and rats 
administered cholesterol. 
The result is presented in Table 2. As seen in the result, 
a significant (p<0.0001) increase in the AIP was 
observed in the hyperlipidemic group in comparison 
with the normal control animals, while in normal rats 
given ML, in comparison with the control, an increase 
was observed in the AIP, despite this, the values 
obtained were still within normal ranges.  Simultaneous 
treatment with all doses of the extract to rats fed on the 
high cholesterol diet significantly (p<0.0001) lowered 
the AIP in comparison with rats fed only on the 
cholesterol. This reduction was dose dependent with 
the 400 mg/kg dose giving the best effect. Atorvastatin 
also produced a significant reduction (p<0.05), although 
the effect of the extract was more prominent. 
 
     Table 2: The Atherogenic index of the various treatment groups 
Treatment (mg/kg) Atherogenic index (AIP) 
Normal rats (2ml/kg distilled water) -0.020 
Hyperlipidemic rats (cholesterol 40mg/rat) 0.640# 
Normal rats + 100 ML 0.064* 
Normal rats + 200 ML 0.053* 
Cholesterol fed rats (40 mg/rat) + 100 ML 0.190* 
Cholesterol fed rats (40 mg/rat) + 200 ML 0.160* 
Cholesterol fed rats (40 mg/rat) + 400 ML 0.060* 
Cholesterol fed rats (40 mg/rat) + 5 atorvastain  0.310a 
n= 6 animals per group. 
#p<0.0001 significantly higher than the normal rats, *p<0.0001 and ap<0.05 significantly lower than the 
hyperlipidemic group 
ML: Aqueous extract of Morinda lucida 
4. Discussion 
Hyerlipidemia was assumed confirmed in all the groups 
fed on the high cholesterol diet because of the 
significant difference in the total cholesterol, 
triglycerides, HDL and LDL values of the Distilled water 
group and the Cholesterol-only group.  
An increase in HDLs indicates a lesser likelihood of 
atherosclerosis, while LDLs may sometimes be referred 
to as “bad fats” and an increase above the threshold 
value of this index indicates a higher likelihood of 
atherosclerosis (Sadur et al, 1984; Chait and Brunzell, 
1990).  
In the present study, Morinda lucida significantly 
increased and lowered these good and bad fats 
respectively. Previous researches have also suggested 
that HDL is more important than the other lipoproteins 
in influencing atherosclerosis; this finding needs to be 
interpreted since there is a close metabolic interrelation 
between lipoprotein species. Recent epidemiological 
studies have elucidated the importance of individual 
lipoproteins in predicting future clinical coronary heart 
disease. HDL appears to exert the greatest influence 
independently of other lipoproteins, with LDL having a 
weaker, though still significant, independent relation 
with coronary heart disease. This correlated negatively 
with HDL and positively with LDL, so probably HDL 
retards while LDL accelerates the development of 
clinical events (Salahuddin and Jalalpure, 2010). It is 
thus safe to say that Morinda lucida will be a good 
alternative to routine hypolipidemic agents such as 
atorvastatin. Apart from the alteration of the abnormal 
values likely to be seen in hyperlipidemia to 
acceptable/normal levels, treatment with ML also 
confers the advantage of retarding the development of 
coronary heart disease and its sequelae.  
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The extract also significantly reduced the total 
cholesterol and triglycerides although its effect on TC 
was not dose dependent, as a lower dose gave a better 
reduction. It is not clear why, although it is not out of 
place to see such results, possibly the active principle 
responsible for the lowering effect may be constant in 
the extract irrespective of the dose used. This was the 
observation, in all, what is important is the lowering 
effect observed at all doses. 
Many laboratories measure the total cholesterol, and 
generally this is equivalent to the LDL level, and the 
lower the better. Low cholesterol and triglyceride levels 
also reduce diabetic complications in addition to lower 
cardiovascular risk (Salahuddin and Jalalpure, 2010). 
The aqueous root extract of Morinda lucida is thus 
important in not just lowering the bad fats, and 
increasing HDL but in addition reduces cardiovascular 
risk and possibly diabetic complications (Owolabi and 
Omogbai, 2013). 
AIP refers to the atherogenic index of plasma and is 
calculated in an attempt to predict cardiovascular risk. 
AIP is based on the ratio of the values of triglycerides to 
high-density lipoprotein (HDL) levels. When placed into 
the scope of AIP, triglycerides and HDL refers to the 
relationship of atherogenic lipids to protective lipids. 
The AIP has demonstrated cardiovascular risk in clinical 
trials. Usually values less than 0.11 indicate low 
cardiovascular risk, values between 0.11 and 0.21 
points to an intermediate risk, while values greater than 
0.21 indicates increased cardiovascular risk, hence 
increased tendency towards myocardial infarction, 
atherosclerosis and ultimately coronary deaths (Onat et 
al, 2010). 
The highest dose of the extract gave an AIP far below 
the 0.11, thus pointing to the protective effect of the 
extract against cardiovascular risk. This positive effect 
(low cardiovascular risk) was observed in both the 
normal rats and rats fed on a high cholesterol diet 
treated with ML.  
Previous studies have shown the antidiabetic effect of 
this plant (Olajide et al, 199; Odutuga et al, 2010; 
Kamanyi et al, 1994), so this present study which points 
to a lowering of the bad lipids and an increase in the 
good lipid coupled with an AIP far less than 0.11 will 
indeed be an advantage to normal, diabetic and 
hyperlipidemic patients. Indeed, even when low density 
lipoprotein cholesterol concentration is normal or 
slightly raised in type 2 diabetes (the major 
abnormalities being low HDL cholesterol and high 
triglyceride concentrations), the patients have a lot to 
benefit from the use of Morinda lucida as shown from 
this present study. Even in situations where the LDL 
particles become qualitatively different and more 
atherogenic than those in non - diabetic patients, the 
use of Morinda lucida still offers protection against 
various cardiovascular risks as proven from its low AIP 
(0.05-0.06). This is in contrast to what was seen in the 
group given only cholesterol, with an AIP of 0.64 which 
is far higher than the 0.21 documented in literature to 
indicate increased cardiovascular risk. 
These effects observed on the lipid profile parameters 
by the extract, may be due to the presence of lipid 
altering secondary metabolites present in the plant. 
Secondary metabolites confirmed in the plant Morinda 
lucida include alkaloids, saponins and sterols.  
From the foregoing and results obtained, it is safe to 
conclude that, the aqueous root extract of Morinda 
lucida possesses antihyperlipidemic effects, as evident 
by the significant reduction in the plasma levels of the 
total cholesterol, triglycerides and low density 
lipoproteins (LDLs) and significant increase in the High 
density lipoproteins (HDLs). Morinda lucida also 
significantly reduced the tendency towards 
cardiovascular risk. 
As a way of continuation in this study, an attempt may 
be made to know which exact secondary plant 
metabolite or principle is responsible for these effects 
seen. And such metabolite if known may serve as a lead 
compound to the discovery of an orthodox 
antihyperlipidemic agent. 
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